.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent clinical evidence suggests that sNfL and atrial fibrillation outcomes are inextricably linked. While serum neurofilament light chain (sNfL) is primarily known as a marker for neuronal injury, its role in predicting cardiovascular risk is becoming clearer. The Swiss Atrial Fibrillation Cohort (SWISS-AF) study recently provided definitive data on this association in a large patient population.
Researchers analyzed 2,311 patients with atrial fibrillation (AF) over a median of eight years. They found that sNfL levels significantly predict the risk of major vascular events (MVEs). Specifically, every doubling of sNfL concentrations increases the adjusted hazard ratio for cardiovascular death, nonfatal stroke, or myocardial infarction to 1.35. Consequently, this biomarker offers a unique perspective on the systemic health of AF patients.
Furthermore, the study highlighted that higher sNfL levels correlate with increased all-cause mortality and heart failure-related hospitalizations. Interestingly, these associations remained robust even after adjusting for traditional risk factors like age, renal function, and prior stroke history. Therefore, sNfL may serve as a powerful tool for clinicians to identify high-risk individuals who require closer monitoring.
Integrating sNfL into standard risk assessment could transform AF management. While current scores focus on clinical history, this blood-based biomarker captures active physiological injury. Additionally, its predictive value for non-neurological outcomes like heart failure suggests that sNfL reflects broader vascular and systemic stress. Clinicians can benefit from this objective measurement to refine patient prognosis and personalize care.
Monitoring sNfL levels can help clinicians identify AF patients at higher risk for cardiovascular death and heart failure, allowing for more intensive monitoring and earlier interventions.
No, latest research from the SWISS-AF cohort indicates it is also a strong independent predictor of major vascular events and all-cause mortality in patients with atrial fibrillation.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare consultation. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Serum neurofilament light chain (sNfL) is identified as a robust biomarker for predicting major vascular events and mortality in atrial fibrillation patient...
6 months ago
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today
In high-risk pulmonary embolism complicated by severe anemia and active uterine bleeding, systemic thrombolysis is contraindicated. Large-bore aspiration thrombectomy provides rapid hemodynamic rescue without fibrinolysis, supported by inferior vena cava filter placement and multidisciplinary critical care.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
